Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.

Itziar Carrasco-García Talia SainzMarie Antoinette FrickSantiago Jiménez de OryClaudia FortunyJoaquin BurgosMarta MonteroCésar GavilánMaría Dolores FalcónJosé Antonio CouceiroJosé Ignacio BernardinoOtilia BisbalCarmelo GuerreroMaría Teresa Aldámiz-EchevarríaJuan BerenguerMaría Luisa Navarronull null

Published in: Journal of viral hepatitis (2020)

Direct-acting antivirals (DAAs) for HCV treatment have improved tolerance and efficacy among adults, but experience in vertical transmission is scarce. In our vertically HIV/HCV co-infected youth cohort of 58 patients, DAA achieved excellent rates of cure among naïve and pretreated individuals. Treating vertically infected seems important as 29.6% displayed advanced fibrosis at treatment initiation.

Keyphrases

hepatitis c virus
human immunodeficiency virus
antiretroviral therapy
hiv infected
hiv positive
mental health
end stage renal disease
ejection fraction
combination therapy
carbon nanotubes